June 12 (UPI) --Doctors have traditionally relied on ultrasounds to examine men for prostate cancer, but the method can't pinpoint specific tumors, a new study says. When researchers combined this ...

BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced the topline results from an investigational clinical trial ...

The test seems likely to improve the diagnosis and treatment of a disease that kills 33,000 American men each year. By Gina Kolata After doctors found cancer in Dr. Mark Samberg’s prostate last spring ...

FDA approves Pylarify TruVu, a new prostate cancer PET imaging agent designed to expand access and improve detection of recurrent or metastatic disease.

Prostate-specific membrane antigen, or PSMA, -targeted PET imaging for prostate cancer has been a breakthrough diagnosis tool in locating prostate cancer tumors for more precise treatment. The new ...

The LOCATE trial was a prospective, U.S., multicenter, open-label study investigating the impact of 18 F-fluciclovine PET/CT imaging on patient management of biochemically recurrent prostate cancer ...

Prostate-specific membrane antigen, or PSMA, -targeted PET imaging for prostate cancer has been a breakthrough diagnosis tool in locating prostate cancer tumors for more precise treatment. The new ...

After doctors found cancer in Dr. Mark Samberg’s prostate last spring, the 70-year-old retired urologist prepared to have his prostate removed. He knew that the surgery would cure him, assuming the ...